Selexis

CSL, Selexis ink commercial license agreement

Wednesday, July 27, 2011

Australia-based CSL has entered into a commercial license agreement with Selexis, headquartered in Switzerland, for the pre-clinical development of a therapeutic antibody anticipated to enter phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.

[Read More]